Background Since the 1960s, beta blockers have been used to treat hypertrophic obstructive cardiomyopathy (HOCM), a genetic ...
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated ...
“The SEQUOIA-HCM trial demonstrated that aficamten can reliably and safely eliminate LVOT obstruction in patients with obstructive HCM using a simple and stepwise dosing regimen, and was associated ...
Beta-blockers have been the cornerstone of treatment for obstructive hypertrophic cardiomyopathy for almost 6 years. Recent data ...
– In a Phase 1 in healthy subjects, EDG-7500 was well-tolerated without meaningful changes in left ventricle ejection fraction (LVEF) – – CIRRUS-HCM single-dose trial of EDG-7500 in obstructive HCM ...
Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
The cardiac myosin inhibitor aficamten (Cytokinetics) is associated with improvements in self-reported health status in patients with obstructive hypertrophic cardiomyopathy (OHCM), according to new ...
The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean ...
Even though mortality and hospitalization rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback